Articles tagged with Androgen Signaling
A retrospective cohort study of 16,924 men found metabolic syndrome and related abnormalities during the first year of treatment. Hypertension was the most common metabolic outcome among patients receiving concurrent androgen deprivation therapy and an androgen receptor pathway inhibitor.
A recent real-world study indicates that reaching a PSA level below 0.2 ng/mL is associated with improved patient survival, and this cutoff may be the best metric for determining treatment success, according to investigators analyzing Veterans Health Administration data.
Research finds ceramide metabolism differences between Black and white individuals with metastatic castration-resistant prostate cancer influence treatment outcomes. Genetic ancestry-related variants affect ceramide levels and ratios, which promote cell survival or death.
A NIH-funded study discovered that testosterone may play a key role in limiting brain tumor growth in men by suppressing inflammation and stress hormone production. Analysis of over 1,300 men with glioblastoma found that supplemental testosterone was significantly associated with improved survival rates.
A study of 2,997 adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and anticoagulants found no increased risks of bleeding or clotting. The findings contradict previous lab results and provide reassurance for clinicians and patients managing anticoagulation alongside modern prostate cancer treatments.
The ASPIRE trial is a Phase III clinical study investigating whether adding chemotherapy to standard treatments can extend survival in men with advanced prostate cancer. The trial aims to determine the effectiveness of combining docetaxel with hormone therapy and apalutamide.
Researchers found that rats with shorter second digits exhibit stronger sexual behavior, including a preference for female scent and frequent ejaculations. This study reveals the impact of fetal hormone exposure on brain development and highlights the link between body and mind.
A study published in PLOS One reveals that cats' purring behavior is linked to genetic variation, specifically the short-type androgen receptor gene. Cats with this gene exhibit higher owner-assessed purring scores than those with the long-type gene.
Researchers identified platelets, C-reactive protein, and chromogranin A as markers that can predict the failure of hormone-sensitive prostate cancer treatment. The study also found that miR-375 expression and lymphocyte-to-monocyte ratio are negative predictors for therapy failure in castration-resistant prostate cancer patients.
Researchers discovered that gut bacteria can transform cholesterol-derived bile acids into powerful metabolites that strengthen anti-cancer immunity by blocking androgen signaling. These microbially modified bile acids antagonize the androgen receptor, driving anti-tumor immunity in mice with bladder cancer.
Researchers discovered TBX2 drives therapy resistance by shifting signaling from the androgen receptor to the glucocorticoid receptor. The study identified a strategy to target this switch, potentially predicting patient risk and offering new treatment approaches.
A recent study reveals genes that may help predict prostate cancer outcomes, including androgen receptor AR-V7 and p160 gene family. The research suggests these genes could serve as potential prognostic biomarkers for prostate cancer, highlighting the importance of androgen signaling in disease progression.
Researchers discovered a novel platinum complex that targets androgen receptor signaling, inhibiting cell growth and survival in prostate cancer cells. The complex, 5-H-Y, showed stronger cytotoxic effects than cisplatin with minimal toxicity, offering a promising approach to treating advanced prostate cancer.
A new study by Weill Cornell Medicine scientists reveals that the enzyme EZH2 drives aggressive tumor growth in treatment-resistant prostate cancers. The absence of protein PKCλ/ι enables EZH2's alternative function, promoting cancer progression despite androgen receptor inhibitors.
Researchers from Radboud University Medical Center discuss the potential of using early on-treatment circulating tumor DNA measurements as a response assessment for metastatic castration-resistant prostate cancer. The detection of ctDNA at baseline and 4-weeks after treatment initiation can predict response durability to first-line ARPIs.
Researchers identify UBE2J1's role in degrading the androgen receptor, a key player in prostate cancer progression. The study suggests targeting this ubiquitination machinery may help overcome antiandrogen resistance in cancer therapy.
A team of researchers used a single-cell transcriptomic map to investigate the role of androgens in shaping sex differences. They identified genes influenced by androgens and found that group 2 innate lymphoid cells play a role in inflammation and disease susceptibility.
Research reveals that males born to obese mothers are more likely to be overweight at birth and develop metabolic complications in later life. The study suggests that male sex hormones play a crucial role in the development of the liver, which can lead to health issues if activated too strongly.
Researchers identified a correlation between the HSD3B1 biomarker and resistance to combined hormone therapy and radiotherapy in men with prostate cancer. The study found that high levels of the enzyme led to increased testosterone production, promoting resistance to treatment.
Scientists at Mays Cancer Center found that altering androgen receptor multivalent interactions may lead to new treatments for prostate cancer. The study suggests that precise levels of these interactions are crucial for proper hormone-induced gene expression.
Men with metastatic prostate cancer in Sweden experienced an average survival rate increase of six months after dual treatment was introduced from 2016 onwards. This improvement coincides with the gradual rollout of 'dual treatment', combining standard hormone therapy and chemotherapy or androgen receptor blockers.
Researchers have found that a prostate cancer drug called proxalutamide can block SARS-CoV-2 viral entry and reduce inflammation. The compound works by binding to androgen receptors, inhibiting levels of TMPRSS2 and ACE2, and blocking infection.
A study has identified a potential treatment target for prostate cancer that is resistant to hormone therapy, a protein modification involving TRAF4. The researchers found that TRAF4 promotes the spread of cancer and may be associated with a new treatment option for patients.
A mouse study suggests that a specific brain receptor, the leptin receptor, may be involved in the development of PCOS symptoms. Researchers found that mice exposed to excess androgens prenatally had improved estrous cycles and regulation of their menstrual cycles, offering potential therapeutic targets for people with PCOS.
Researchers investigated point mutations in the androgen receptor, which affect its function and lead to diseases such as prostate cancer. The study found that these mutations deregulate posttranscriptional modifications, causing functional changes and pathologies.
Researchers discovered that androgen therapy alters the organization of cells within breast tissue, reducing signs of estrogen influence and changing protein production. The findings could lead to new therapies for estrogen receptor-positive breast cancer.
Researchers have identified mitochondrial signaling pathways as critical organelles that promote tumorigenesis and metastasis. In particular, the integrated stress response is found to engage with mitochondria to drive tumor growth, highlighting a new paradigm for understanding aggressive prostate cancer progression.
Researchers at Baylor College of Medicine discovered a novel approach to suppress the growth of therapy-resistant prostate cancer tumors. By enhancing GATA2 degradation, the study found marked suppression of tumor growth and castration resistance in animal models.
A new study reveals that androgen receptor inhibitors can fundamentally rewire prostate tumors, making them more aggressive. The researchers found that most tumors remain fuel-dependent after treatment, but a small percentage convert to double-negative prostate cancer.
Researchers at LSU Health Sciences Center have discovered a novel combination therapy that effectively treats chemo-resistant triple-negative breast cancer. The treatment combines two existing FDA-approved drugs, ceritinib and enzalutamide, to target the growth of cancer cells, showing promise for improving treatment outcomes.
A new study published in Science Translational Medicine reveals that consecutive molecular modifications of the androgen receptor can contribute to drug resistance in prostate cancer. Researchers identified a potential treatment approach using an ACK1 inhibitor to block this resistance.
Researchers found higher AR signaling and better response rates for female patients treated with BRAF/MEK inhibitors. Blocking the AR improved response to BRAF/MEK targeted therapy in both males and females.
A group of researchers led by Indiana University School of Medicine's Benjamin Gaston will receive a research program project grant to fund the development of personalized therapeutic approaches for severe asthma. The grant will support three key projects focused on S-nitrosylation signaling, airway pH regulation, and androgen signaling.
The ARAMIS phase III clinical trial found that darolutamide improved metastasis-free survival and overall survival in Black/African American patients. Darolutamide-treated patients had a higher three-year overall survival rate and longer time to disease progression compared to placebo-treated patients.
Researchers identify lineage plasticity as a deadly identity switch in castration-resistant prostate cancers, which can behave like small cell lung cancer. BET bromodomain inhibitors show promise in blocking this switch and overcoming treatment-emergent neuroendocrine prostate cancer.
Researchers discovered that targeting androgen receptors can destroy bladder cancer cells. The study found a common protein variant in malignant bladder tumor cells, which could lead to new therapeutic strategies.
Researchers have found that androgen receptor activation by natural androgens or a new drug has potent anti-tumour activity in all estrogen receptor positive breast cancers, even those resistant to current treatments. This study provides new evidence for an alternative treatment strategy.
Researchers found that blocking the androgen receptor reduces coronavirus infection in mice and cellular models. Anti-androgen treatments are already FDA-approved, opening up potential COVID-19 treatment options.
Researchers at Baylor College of Medicine have discovered a new site on the androgen receptor that interacts with activity-enhancing coactivators, driving prostate cancer growth. The study's findings provide insights into the design of future treatments for this devastating condition.
Researchers discovered that activating the androgen receptor decreases tumor growth in estrogen receptor-positive (ER+) breast cancer. The study used enobosarm, an androgen receptor-stimulating drug, which stopped tumor growth in all models tested.
Researchers discovered an alternative pathway for testosterone production that contributes to the development of male characteristics in human girls with a genetic disorder. The study found this pathway is present and active during fetal development and plays a key role in shaping external genitalia in newborns with CAH.
A large population-based study found that novel oral androgen signaling inhibitor therapies increase the risk of death in patients with pre-existing cardiovascular conditions. Patients with three or more heart conditions experienced a 50% increase in mortality, while enzalutamide was associated with lower hospitalization rates.
A study found that chaperone protein Hsp70 inhibits toxic protein aggregates in the androgen receptor, which causes Kennedy's disease and prostate cancer. Hsp70 may be useful as a therapeutic target to treat these conditions.
Researchers at Boston University School of Medicine have discovered that inhibiting the BRD4 protein can consistently regulate prostate cancer cell migration and invasion. The study provides promising insights into preventing the spread of castration-resistant prostate cancer (CRPC), a highly aggressive form of the disease.
Researchers at UIC will study mangosteen's phytochemicals and their impact on prostate cancer cells, with the goal of developing a new treatment approach. The $1.7M grant from NCI aims to investigate the unique xanthones in mangosteen that promote androgen receptor degradation.
Recent advancements in prostate imaging modalities have significantly enhanced the diagnosis of prostate cancer. Androgen receptor-based imaging is emerging as a promising approach for non-invasive detection using non-steroidal antiandrogen agents.
A study has identified 600 novel long noncoding RNA molecules that regulate the effects of androgens and androgen receptors on gene expression in prostate tumors. These lncRNAs are powerful regulators of gene expression and interact with and magnify the effect of regulatory proteins, suggesting a new target for treatment.
A novel long non-coding RNA, ARLNC1, controls signals from the androgen receptor, a key player in prostate cancer. Knocking down this RNA led to cancer cell death, suggesting it as a potential target for future therapies.
IRB Barcelona researchers have discovered a new target for treating advanced prostate cancer, the TFIIF protein. Removing this protein's interaction with the androgen receptor could make treatment effective again in resistant tumors.
A new study published in Nature Communications describes the unique role of androgens in kidney cancer, suggesting a potential new approach to treatment. Researchers found that androgen signaling can either stimulate or suppress tumor cell movement and invasion, with male patients being more likely to spread to the lungs.
Androgen receptor targeted imaging is emerging as a potential modality for early, rapid, and efficient diagnosis of prostate cancer. Current medical imaging reviews discuss traditional diagnostic approaches and summarize current imaging approaches using PSMA, BN, and AR targeted imaging.
New research suggests that male hormones promote infection with the virus that causes Kaposi's sarcoma, a type of cancer. The study found that androgen receptors in cells are activated by male hormones, leading to increased levels of KSHV genetic material detected in infected men.
A study published in Hormones & Cancer found that obese rats with sensitive androgen receptors had more aggressive tumors, even after anti-estrogen treatment. Researchers identified inflammation and cytokine interleukin 6 as key factors contributing to this sensitivity, highlighting the potential for personalized therapeutic strategies.
Researchers at Duke University discovered that CYP17A1 inhibitors function as competitive AR antagonists, indicating a more effective role in treating prostate cancer. The study found that these inhibitors can inhibit the growth of prostate tumor cells expressing treatment-resistant AR mutations.
Researchers at University of Alabama at Birmingham discovered endostatin's ability to decrease castration-resistant prostate cell growth in culture. Endostatin reduces oxidative stress and targets hormone receptors, shifting metabolism to scavenge reactive oxygen species.
Researchers discovered a new mechanism explaining BPH development, linking inflammation and cell proliferation. Deleting the androgen receptor in prostate epithelial cells triggers an inflammatory response promoting luminal cell proliferation.
Researchers at Duke University Medical Center report a novel compound, tetraaryl cyclobutane (CB), that blocks testosterone from fueling prostate tumor growth in mice. The compound has a unique mechanism of action and may be effective against prostate tumors resistant to current anti-androgen drugs.
Researchers developed an analog of an investigational drug that binds to portions of the androgen receptor common to full-length and variant forms. This compound specifically detected prostate cancer cells expressing androgen receptor in a mouse model using SPECT/CT imaging.
Researchers at Karolinska Institutet and University of Oulu identified mechanisms explaining genetic variants' influence on prostate cancer risk. The study reveals widespread deregulation of androgen receptor function, a key player in prostate cancer.
A phase 1 clinical trial found that enzalutamide is active and well-tolerated alone and with fulvestrant in patients with advanced breast cancer. The study supports a larger trial of the combination, building on promising preclinical data and targeting androgen receptors in breast cancer.